Dr. Agarwal's Health Care Limited has announced that its officials will participate in a series of investor conferences and meetings scheduled from May 28, 2026, to June 16, 2026. The disclosure was made in accordance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The scheduled meetings will cover both group and one-on-one interactions and will be conducted in physical mode across various locations. The events are organized by prominent financial institutions, including 360 ONE Capital, Avendus, and Kotak.

Schedule of Meetings

The following table outlines the specific dates, organizers, and locations for the upcoming investor interactions:

Disclosure Policy

The company stated that these meetings will adhere to its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. Consequently, no unpublished price-sensitive information or forward-looking statements will be disclosed or discussed during the analyst and investor meetings. Dr. Agarwal's Health Care Limited also noted that the schedule is subject to changes due to exigencies on the part of the analysts, investors, or the company.

Dr. Agarwal's Health Care reported a robust financial performance for the year ended March 31, 2026, with Profit After Tax (PAT) growing 52.4% year-on-year to INR 168 Crores. The company achieved a significant operational milestone, with Revenue from Operations increasing 21.6% to INR 2,080 Crores, crossing the INR 2,000 Crore mark for the first time. EBITDA for the period rose 22.2% to INR 614 Crores, with margins expanding to 28.9%. Following the announcement, the company has made the audio recording of its analyst and earnings conference call held on May 21, 2026, available on its website.

Annual Financial Performance

The audited consolidated financial results highlight strong growth across key metrics. Total Income for the year stood at INR 2,125 Crores, a 20.9% increase compared to the previous year. The company maintained its operational efficiency, with EBITDA margins improving slightly from 28.6% in FY25 to 28.9% in FY26. Net profit margins also saw a significant rise, reaching 7.9% for the year.

Operational Expansion

During FY26, the company expanded its network significantly, adding 57 new centers to take its total facility count to 288 across 10 countries. This included 30 surgical centers, strengthening clinical capacity. The company performed 323,245 surgeries during the year, reflecting a 14.5% growth in patient volumes. The entry into the Delhi NCR region was a key highlight, with six facilities becoming operational within twelve months.

Q4 Performance Highlights

For the quarter ended March 31, 2026, the company reported a Revenue from Operations of INR 564 Crores, up 22.6% year-on-year. Net profit for the quarter stood at INR 50 Crores, growing 17.4% YoY. EBITDA for Q4 FY26 was INR 174 Crores, with margins at 30.2%. The company added 19 new centers during the quarter alone, comprising 7 secondary and 12 primary facilities.